Advertisement
Advertisement
GPCR
Structure Therapeutics Inc. - ADR
53.14
USDSponsored
+0.52
+0.99%
Aug 07, 15:58 UTC -4
Closed
After-Market
55.42
+2.28
+4.30%
GPCR Earnings Reports
Positive Surprise Ratio
GPCR beat 2 of 14 last estimates.
14%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.44
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-60.36%
Structure Therapeutics Inc. - ADR earnings per share and revenue
On Aug 04, 2026, GPCR reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.40 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.79% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.44 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
FAQ
What were Structure Therapeutics Inc. - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Structure Therapeutics Inc. - ADR reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Structure Therapeutics Inc. - ADR's Q2 2026 earnings?
The stock price moved up 1.79%, changed from $49.64 before the earnings release to $50.53 the day after.
When is Structure Therapeutics Inc. - ADR expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Structure Therapeutics Inc. - ADR's next earnings report?
Based on 12
analysts, Structure Therapeutics Inc. - ADR is expected to report EPS of -$0.44 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement